Adam Kittai, MD, Ohio State University, Columbus, OH, outlines promising therapies currently under investigation for the treatment of Richter's transformation in the first-line setting, including the combination of venetoclax and R-CHOP, pirtobrutinib, epcoritamab, and CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть